A primer-probe combination, kit and detection method for detecting tuberculosis and non-tuberculous mycobacteria
Through dual RAA-LFD technology, the special primer probe composition and double-standard nucleic acid detection test strips are used to achieve rapid and accurate identification of tuberculosis and non-tuberculosis, and the difficulty and cost of identification in the prior art are solved. The problem is that high sensitivity and specificity detection effect is achieved.
Patent Information
- Application Number
- CN202211578360.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-06
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-12-06
AI Technical Summary
The prior art is difficult to quickly, accurately, easily and at low cost to distinguish M. tuberculosis and non-tuberculosis, especially the four common intracellular mycobacterium avians, Mycobacterium Kansas and Mycobacterium abscess, for clinical diagnosis and treatment. There are problems of identification difficulties and high cost.
Using dual recombinase-assisted isothermal amplification (RAA) combined with lateral flow chromatography test strip (LFD) technology, a reaction detection of special primer probe composition is carried out to achieve rapid and accurate tuberculosis and non-tuberculous mycobacterium Identification, including designing specific nucleotide sequences and modified marker upstream and downstream primers and probes, combining Bst polymerase and single-strand binding protein, DNA amplification using constant temperature conditions, and performing through double-standard nucleic acid detection test strips Visual detection.
It realizes rapid and accurate identification of four common mycobacteria, reduces detection cost and time, has high sensitivity and specificity, can quickly amplify under constant temperature conditions of 37-42℃, and the results are readable by the naked eye, suitable for resources In limited areas, detection limit reaches a single copy/response.
Smart Images

Figure CN115927686B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a primer-probe composition, a kit and a detection method for detecting tuberculosis and non-tuberculous mycobacteria. Background Art
[0002] Mycobacteria are mainly divided into three categories, namely, Mycobacterium tuberculosis complex (MTC), Mycobacterium leprae and non-tuberculous mycobacteria (NTM). Among them, tuberculosis caused by Mycobacterium tuberculosis has been the leading cause of death in humans due to single pathogen infection for many years.
[0003] However, in recent years, the clinical incidence of NTM (nontuberculous mycobacteria) infection has continued to rise, among which the most common are Mycobacterium avium intracellulare, Mycobacterium kansasii, and Mycobacterium abscessus, accounting for more than 90% of the total NTM clinical isolates. Their clinical symptoms are very similar to those of MTB (Mycobacterium tuberculosis) infection, but the treatment plans for the two are very different. In clinical diagnosis and treatment, the accurate identification of NTM and MTB is an important hot and difficult issue, and rapid and accurate testing methods are urgently needed for the identification of mycobacterial species.
[0004] Recombinase-assisted isothermal amplification (RAA) is a new isothermal in vitro nucleic acid amplification technology. Its principle is that the protein-DNA complex formed by the combination of recombinase and primer can find homologous sequences in double-stranded DNA. Once the primer locates the homologous sequence, a strand exchange reaction will occur and initiate DNA synthesis, exponentially amplifying the target region on the template.
[0005] The advantages of this method include: ① low equipment cost; ② constant temperature operation, usually at 37-42°C; ③ short time, reaching detectable levels within 10 minutes; ④ high sensitivity; ⑤ strong specificity.
[0006] RAA can be used in combination with lateral flow dipstick (LFD). In the RAA amplification system, a biotin-labeled reverse primer and a fluorescein-labeled probe are required. The probe can be recognized by the nfo enzyme and extended under the action of DNA polymerase to form a RAA product with biotin and fluorescein double labels, and then the product is detected by LFD. The LFD sample end is coated with gold nanoparticles with fluorescein antibodies, and the detection line is coated with biotin antibodies. When the reaction solution enters the test strip, the amplification product with fluorescein and biotin will form a complex on the detection line through antigen-antibody binding and color development. The detection time is short and can be read by the naked eye.
[0007] The main methods currently used in clinical practice to differentiate between MTB and NTM are:
[0008] (1) p-Nitrobenzoic acid selective culture medium method: ① It is time-consuming; ② It is not possible to perform interspecies identification.
[0009] (2) Linear probe hybridization technology: ① Time-consuming; ② High cost; ③ High false positive rate.
[0010] (3) DNA sequencing: ① Expensive; ② Complex technology; ③ Large equipment limitations.
[0011] (4) Bacterial culture combined with mass spectrometry identification: It takes a very long time (about 1 month). Therefore, there is an urgent need for a fast, accurate, simple and low-cost method for identifying MTB and NTM. Summary of the invention
[0012] In view of the shortcomings of the prior art, the present invention aims to provide an innovative detection invention which can detect and identify four mycobacteria in one reaction, and is rapid, sensitive, specific, accurate and highly visualized. The invention comprises a primer-probe combination and a kit that can be used to detect tuberculosis and non-tuberculosis mycobacteria and a corresponding detection method.
[0013] (I) In order to achieve the above-mentioned object, the present invention adopts the following technical scheme: A primer-probe composition for detecting tuberculosis and non-tuberculous mycobacteria specifically comprises:
[0014] 1. A composition 1 for detecting Mycobacterium tuberculosis comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO: 1; a downstream primer having a nucleotide sequence as shown in SEQ NO: 2; and a probe having a nucleotide sequence as shown in SEQ NO: 3;
[0015] 2. Composition 2 for detecting non-tuberculous mycobacteria comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO:4; a downstream primer having a nucleotide sequence as shown in SEQ NO:5; and a probe having a nucleotide sequence as shown in SEQ NO:6;
[0016] 3. Composition 3 for detecting non-tuberculous mycobacteria comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO: 7; a downstream primer having a nucleotide sequence as shown in SEQ NO: 8; and a probe having a nucleotide sequence as shown in SEQ NO: 9;
[0017] 4. Composition 4 for detecting non-tuberculous mycobacteria comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO: 10; a downstream primer having a nucleotide sequence as shown in SEQ NO: 11; and a probe having a nucleotide sequence as shown in SEQ NO: 12.
[0018] (II) Application scope of each composition:
[0019] 1. The composition 2 is used to detect Mycobacterium avium-intracellulare complex; the composition 3 is used to detect Mycobacterium kansasii; and the composition 4 is used to detect Mycobacterium abscessus.
[0020] 2. The labeling method of each composition is:
[0021] ① The 5' ends of SEQ NO: 2 and SEQ NO: 10 are modified with biotin;
[0022] ② The 5' end of SEQ NO: 3 and SEQ NO: 12 is modified with FAM, the 31st base from the 5' end is modified with tetrahydrofuran (THF), and the 3' end is provided with a polymerase extension blocking group C3 spacer;
[0023] ③ The 5' end of SEQ NO:5 was modified with rhodamine TAMRA;
[0024] ④ The 5' end of SEQ NO: 6 is modified with Digxin, the 30th base from the 5' end is modified with tetrahydrofuran (THF), and the 3' end has a polymerase extension blocking group C3 spacer;
[0025] ⑤ The 5' end of SEQ NO: 8 is modified with TAMRA and Digxin, and the 3' end has a polymerase extension blocking group C3 spacer;
[0026] ⑥ The 32nd base from the 5' end of SEQ NO:9 was modified with tetrahydrofuran (THF).
[0027] (III) Composition of the kit:
[0028] 1. A kit for detecting tuberculosis and non-tuberculous mycobacteria, comprising the above primer-probe combination, and also comprising a buffer, RNase-free water, magnesium acetate, a PCR tube containing lyophilized enzyme powder, a double-labeled nucleic acid detection test strip, a positive standard and a negative standard.
[0029] 2. Secondly, further, the PCR tube containing the lyophilized enzyme powder contains Bst polymerase and single-stranded binding protein;
[0030] 3. The positive standard is genomic DNA of Mycobacterium tuberculosis, Mycobacterium intracellulare, Mycobacterium abscessus and Mycobacterium kansasii;
[0031] 4. The negative standard is PBS solution.
[0032] (IV) Test kit testing process:
[0033] 1. A detection method of a kit for detecting tuberculosis and non-tuberculous mycobacteria, the detection method and process comprising: (1) extraction of genomic DNA of a sample to be tested; (2) RAA amplification reaction; (3) LFD reaction. The (1) is obtained by high temperature lysis method. The specific steps of the (2) include:
[0034] 2. Add the genomic DNA in (1) to the PCR tube containing the reaction system and freeze-dried enzyme powder, shake for 1 second, centrifuge for 1 second, repeat 3 times to fully mix, transfer the reaction tube to a metal bath, heat at 37°C for 30 minutes, replace the genomic DNA with the negative standard for the negative control, and replace the genomic DNA with the positive standard for the positive control.
[0035] 3. Furthermore, the specific steps of (3) include:
[0036] The amplification product obtained in (2) was diluted 25 times with magnesium acetate, and the mixture was added to the sample pad of the double-labeled nucleic acid detection test strip. The result was read after reacting for 5 minutes.
[0037] (V) The benefits of the present invention "a primer-probe combination, a kit and a detection method for detecting tuberculosis and non-tuberculous mycobacteria" are mainly:
[0038] The present invention adopts dual RAA-LFD detection, and realizes differential diagnosis of four common mycobacteria in one reaction: Mycobacterium tuberculosis, Mycobacterium avium intracellulare complex, Mycobacterium kansasii, and Mycobacterium abscessus. LFD is introduced on the basis of dual RAA for rapid, accurate and visual detection, which greatly reduces the detection cost and shortens the detection time. No expensive machines are required, amplification is performed at a constant temperature, and the results are interpreted by the naked eye. It has ultra-high sensitivity, and the detection limit can reach a single copy / reaction at most. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 The specificity verification results of dual RAA-LFD for tuberculosis and Mycobacterium avium-intracellulare in the examples of the present invention are as follows;
[0040] Figure 2 The specificity verification results of dual RAA-LFD of Kansas and Mycobacterium abscessus in the embodiments of the present invention are as follows;
[0041] Figure 3 The sensitivity verification result of Mycobacterium tuberculosis in the embodiment of the present invention is shown;
[0042] Figure 4 This is the sensitivity verification result of Mycobacterium intracellulare in the embodiment of the present invention;
[0043] Figure 5 This is the sensitivity verification result of Mycobacterium kansasii in the embodiment of the present invention;
[0044] Figure 6 This is the sensitivity verification result of Mycobacterium abscessus in the embodiment of the present invention. DETAILED DESCRIPTION
[0045] The specific implementation manner will be further described below in conjunction with the accompanying drawings.
[0046] The reagents and instruments in the following examples are all conventional experimental reagents and instruments.
[0047] Embodiment 1:
[0048] A primer-probe combination for detecting tuberculosis and non-tuberculous mycobacteria, as shown in Table 1:
[0049] Table 1
[0050]
[0051] 1. The 5' ends of SEQ NO: 2 and SEQ NO: 10 are modified with biotin;
[0052] 2. The 5' end of SEQ NO: 3 and SEQ NO: 12 is modified with FAM, the 31st base from the 5' end is modified with tetrahydrofuran (THF), and the 3' end is provided with a polymerase extension blocking group C3 spacer;
[0053] 3. The 5' end of SEQ NO:5 was modified with rhodamine TAMRA;
[0054] 4. The 5' end of SEQ NO: 6 is modified with Digxin, the 30th base from the 5' end is modified with tetrahydrofuran (THF), and the 3' end has a polymerase extension blocking group C3 spacer;
[0055] 5. The 5' end of SEQ NO: 8 is modified with TAMRA and Digxin, and the 3' end has a polymerase extension blocking group C3 spacer;
[0056] 6. The 32nd base from the 5' end of SEQ NO:9 was modified with tetrahydrofuran (THF).
[0057] Embodiment 2:
[0058] A kit for detecting tuberculosis and non-tuberculous mycobacteria, comprising the primer-probe combination of the above embodiment 1,
[0059] Also included are reagent 1 (tris-HCl and potassium chloride buffer), reagent 2 (RNase-free water), reagent 3 (magnesium acetate), PCR tubes containing lyophilized enzyme powder, double-labeled nucleic acid detection test strips, positive standards, and negative standards.
[0060] The PCR tube containing the freeze-dried enzyme powder contains Bst polymerase and single-stranded binding protein;
[0061] The positive standard substance is the genomic DNA of Mycobacterium tuberculosis, Mycobacterium intracellulare, Mycobacterium abscessus and Mycobacterium kansasii; the negative standard substance is PBS solution.
[0062] The kit of the present invention has high detection specificity and ultra-high sensitivity, and is efficient and rapid in detection. It has a wide range of application potentials in mycobacterium detection:
[0063] 1. Achieve differential diagnosis of four common mycobacteria: Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex, Mycobacterium kansasii, and Mycobacterium abscessus.
[0064] 2. Short time and low cost: The isothermal amplification time is short, the equipment is relatively cheap, the lateral flow chromatography technology is simple to prepare, easy to detect, low cost, and the detection time is short.
[0065] 3. Few detection restrictions and easy to promote and apply: Constant temperature amplification can quickly amplify to detectable levels at a single constant temperature of 37°C to 42°C. It is easy to operate, making it a promising alternative method for on-site testing in areas with scarce resources and a high burden of infectious diseases.
[0066] 4. Fewer primers are required: Compared with other commonly used isothermal amplification technologies, LAMP, it only requires one pair of primers to detect the target, making it more suitable for the construction of multiplex systems.
[0067] 5. Good specificity and high sensitivity: It can specifically identify Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex, Mycobacterium kansasii, and Mycobacterium abscessus, with the lowest detection limits of 2.0fg / μL, 3.2fg / μL, 4.1fg / μL, and 3.5fg / μL, respectively.
[0068] Embodiment 3:
[0069] A method for detecting tuberculosis and non-tuberculous mycobacteria,
[0070] 1. Genome Extraction
[0071] The DNA template of the sample to be tested was extracted and purified by the modified CTAB method. The CTAB reagent was purchased from Solebao Company. The operation is as follows:
[0072] (1) Collect fresh mycobacterial culture (50-100 mg) with physiological saline and place in a 1.5 ml EP tube. Inactivate in a metal bath at 80°C for 30 min. Centrifuge at 12,000 r / min (centrifugal radius 10 cm) for 5 min, discard the supernatant, resuspend the bacterial pellet in 400 μL TE buffer, then add 50 μL lysozyme (10 mg / mL), shake and mix, and incubate at 37°C for 16-20 h.
[0073] (2) Add 5 μL of RNase A and invert several times to mix.
[0074] (3) Add 70 μL of 10% SDS and 5 μL of proteinase K (20 mg / mL) solution, mix thoroughly by inversion, and incubate at 65°C for 10 min.
[0075] (4) Add 100 μL 5 mol / L NaCl and 100 μL CTAB / NaCl respectively, vortex mix until the liquid turns milky white, and incubate at 65°C for 10 min.
[0076] (5) Add 750 μL of chloroform, invert to mix, and centrifuge at 12,000 r / min (centrifugal radius 10 cm) for 5 min. Transfer the supernatant to another EP tube and add 0.6 times the volume (about 450 μL) of pre-cooled isopropanol to precipitate the DNA. After standing at -20°C for 30 min, centrifuge at 12,000 r / min (centrifugal radius 10 cm) for 15 min.
[0077] (6) Discard the supernatant, wash the DNA precipitate with 1 mL of 70% ice ethanol, and centrifuge at 12,000 r / min (centrifugal radius 10 cm) for 5 min. Remove as much liquid as possible from the tube and dry at 37°C for 10 min.
[0078] (7) Dissolve the DNA precipitate in 50 μL TE buffer and store at -20°C.
[0079] 2. RAA amplification reaction
[0080] (1) Detection of tuberculosis and Mycobacterium avium-intracellulare complex
[0081] The extracted genome was used as a template for RAA reaction. The reaction system is shown in Table 2:
[0082] Table 2
[0083]
[0084] (2) Detection of Mycobacterium kansasii and Mycobacterium abscessus complex
[0085] The extracted genome was used as a template for RAA reaction. The reaction system is shown in Table 3:
[0086] Table 3
[0087]
[0088]
[0089] The above reaction system was shaken for 1s, centrifuged for 1s, and repeated 3 times to mix thoroughly. The reaction tube was then transferred to a metal bath and heated at 37°C for 30min. For the negative control, the 4μL template DNA was replaced by 4μL negative standard. For the negative control, the 4μL template DNA was replaced by 4μL positive standard. Other reaction conditions were the same.
[0090] 3. LFD reaction
[0091] Take a certain amount of amplification product and dilute it 25 times with solution 3, then take 50 μL of the mixture and add it to the sample pad of the colloidal gold test strip, and read the result after reacting for 5 minutes.
[0092] When 2 or 3 bands appear on the test strip (1 blue band appears at the quality control line and 1 or 2 red bands appear at the test line), the test result is positive. If a red band appears on the test line closer to the quality control line, it indicates infection with avian intracellular Mycobacterium avium, and if the test line farther from the quality control line is red, it indicates infection with Mycobacterium tuberculosis. If red bands appear on both test lines, it indicates mixed infection with Mycobacterium tuberculosis and avian intracellular Mycobacterium avium. When a blue band appears at the quality control line of the test strip, the test result is negative. If no bands appear at both the quality control line and the test line, the test result is invalid.
[0093] After liquefaction with 10% NaOH, the nucleic acid sample was extracted by the concentration and lysis method, and detected by the RAA-LFD established by the present invention. The detection results were compared with the BD960 culture and mass spectrometry results, and the positive sample detection rate was well consistent with the BD960 culture and mass spectrometry results.
[0094] Embodiment 4:
[0095] Analysis of the diagnostic performance of a test kit for detecting tuberculosis and nontuberculous mycobacteria,
[0096] 1. Specificity detection
[0097] Genomic DNA was extracted from Mycobacterium sugae, Mycobacterium gordonii, Mycobacterium chelonae, Mycobacterium scrofulae, Mycobacterium malmoe, Mycobacterium fortuitum, Mycobacterium chimaera, and common respiratory bacteria such as Klebsiella pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, and Acinetobacter baumannii.
[0098] Mycobacterium tuberculosis (37Ra) was preserved in this laboratory; other isolates were identified by mass spectrometry; the dual RAA-LFD detection method of Example 3 was used to perform specific detection on the above genomic DNA, with reagent 3 as a blank control, and the specificity of the established detection method was determined based on the test strip test results.
[0099] RAA-LFD test results (such as Figure 1 , 2 )show, Figure 1 Among them, ①: tuberculosis, intracellular mycobacterium; ②: intracellular mycobacterium; ③: Mycobacterium tuberculosis; ④: solution 3; 5-15: Kansas, abscess, Suga, Gordon, turtle, scrofula, Malmo, smegma, fortuitous, chimera, Geneva Mycobacterium; 16-22: Klebsiella pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Acinetobacter baumannii.
[0100] Mycobacterium tuberculosis and Mycobacterium avium-intracellulare complex showed red bands, indicating a positive result. Other NTM, common respiratory bacteria, and negative controls did not show red bands, indicating negative results.
[0101] Figure 2 Among them, ①: Kansas, Mycobacterium abscessus; ②: Mycobacterium kansas; ③: Mycobacterium abscessus; ④: Solution 3; 5-15: Tuberculosis, intracellular, Suga, Gordon, Turtle, scrofula, Malmo, smegma, fortuitous, chimera, Mycobacterium geneva; 16-22: Klebsiella pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Acinetobacter baumannii.
[0102] Kansasii Mycobacterium and abscessus Mycobacterium showed red bands, indicating a positive result, while other NTM, common respiratory bacteria and negative controls did not show red bands, indicating negative results, indicating that the present invention has high specificity and will not cause cross-reaction.
[0103] 2. Sensitivity test
[0104] The concentrations of the extracted genomic DNA of Mycobacterium tuberculosis, Mycobacterium intracellulare, Mycobacterium kansasii and Mycobacterium abscessus were measured using an ultraviolet spectrophotometer, and the DNA was diluted 10 times with reagent 3, and detected according to the dual RAA-LFD detection method of Example 3.
[0105] RAA-LFD sensitivity results ( Figure 3-6 ) showed that the minimum detection limit of Mycobacterium tuberculosis was 2.0fg / μL; the minimum detection limit of Mycobacterium avium intracellulare complex was 3.2fg / μL; the minimum detection limit of Mycobacterium kansasii was 4.1fg / μL; and the minimum detection limit of Mycobacterium abscessus was 3.5fg / μL, indicating that this method has good sensitivity.
[0106] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable ordinary technicians in the field to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made based on the essence of the content of the present invention should be included in the protection scope of the present invention.
Claims
1. A primer-probe combination for detecting tuberculosis and non-tuberculous mycobacteria, Its characteristics are: The composition 1 for detecting Mycobacterium tuberculosis comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO: 1; a downstream primer having a nucleotide sequence as shown in SEQ NO: 2; and a probe having a nucleotide sequence as shown in SEQ NO: 3; Composition 2 for detecting non-tuberculous mycobacteria comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO:4; a downstream primer having a nucleotide sequence as shown in SEQ NO:5; and a probe having a nucleotide sequence as shown in SEQ NO:6; The composition 3 for detecting non-tuberculous mycobacteria comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO:7; a downstream primer having a nucleotide sequence as shown in SEQ NO:8; and a probe having a nucleotide sequence as shown in SEQ NO:9; The composition 4 for detecting non-tuberculous mycobacteria comprises: an upstream primer having a nucleotide sequence as shown in SEQ NO: 10; a downstream primer having a nucleotide sequence as shown in SEQ NO: 11; and a probe having a nucleotide sequence as shown in SEQ NO: 12; The composition 2 is used to detect Mycobacterium avium intracellulare complex; the composition 3 is used to detect Mycobacterium kansasii; the composition 4 is used to detect Mycobacterium abscessus; The 5' ends of SEQ NO: 2 and SEQ NO: 10 are modified with biotin; The 5' end of SEQ NO:3 and SEQ NO:12 is modified with FAM, the 31st base from the 5' end is modified with tetrahydrofuran (THF), and the 3' end is provided with a polymerase extension blocking group C3 spacer; The 5' end of SEQ NO:5 was modified with rhodamine TAMRA; The 5' end of SEQ NO: 6 is modified with Digxin, the 30th base from the 5' end is modified with tetrahydrofuran (THF), and the 3' end has a polymerase extension blocking group C3 spacer; The 5' end of SEQ NO: 8 is modified with TAMRA and Digxin, and the 3' end has a polymerase extension blocking group C3spacer; The 32nd base from the 5' end of SEQ NO:9 was modified with tetrahydrofuran (THF).
2. A kit for detecting tuberculosis and non-tuberculous mycobacteria, Features: comprising the primer-probe combination according to claim 1, Also included are buffer, RNase-free water, magnesium acetate, PCR tubes containing lyophilized enzyme powder, double-labeled nucleic acid detection strips, positive standards, and negative standards.
3. The kit for detecting tuberculosis and non-tuberculous mycobacteria according to claim 2, Features: The PCR tube containing the freeze-dried enzyme powder contains Bst polymerase and single-stranded binding protein; The positive standards are genomic DNA of Mycobacterium tuberculosis, Mycobacterium intracellulare, Mycobacterium abscessus and Mycobacterium kansasii; The negative standard is a PBS solution.
